OncoSKY Global shared a post on LinkedIn:
“OncoSKY Diagnostic Reasoning Series.
STOP MISUSING PD-L1.
PD-L1 is not a binary switch. It is a context-dependent predictive biomarker.
Common pitfalls we still see in daily practice:
- Assuming assays are interchangeable.
- Mixing TPS, CPS, and IC scoring systems.
- Ignoring tumor-specific regulatory context.
- Over-interpreting PD-L1 <1% outside NSCLC chemo-IO.
Before prescribing immunotherapy, pause and check:
- Tumor type.
- Correct scoring system for that tumor.
- Assay clone used.
- Regulatory cut-off for that indication.
- Line of therapy and regimen context.
PD-L1 modifies probability – not certainty. Never treat the number. Treat the context.”
Other articles about PD-L1 on OncoDaily.